key: cord-0860940-zssmhgbe authors: Vatsalya, V.; Li, F.; Frimodig, J. C.; Gala, K. S.; Srivastava, S.; Kong, M.; Ramchandani, V. A.; Feng, W.; Zhang, X.; McClain, C. J. title: Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic Profile date: 2020-08-25 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2020.08.23.20177501 sha: 297c21f1b4498547ee08c4935ac6c7f9577d0588 doc_id: 860940 cord_uid: zssmhgbe Introduction Emerging infectious diseases, especially the coronavirus disease identified in 2019 (COVID-19), can be complicated by a severe exacerbation in the Th17 cell-mediated IL-17 proinflammatory immune storm. This enhanced immune response plays a major role in mortality and morbidity, including neurological symptoms. We hypothesized that countering the cytokine storm with thiamine may have therapeutic efficacy in lowering the Th17 cell proinflammatory response. We used an in vitro study and corroborated those results in disease controls (DC). We developed an effective dose range and model for key pharmacokinetic measures with the potential of targeting the cytokine storm and neurological symptoms of COVID-19. Study Participants and Methods We investigated the effect of a three-week 200 mg dose of thiamine in lowering the Th17 response in sixteen DC (proinflammatory origin due to heavy alcohol drinking) patients; and eight healthy control/volunteers (HV) as a pilot clinical-translational investigation. To further investigate, we performed an in vitro study evaluating the effectiveness of thiamine treatment in lowering the Th17 proinflammatory response in a mouse macrophage cell line (RAW264.7) treated with ethanol. In this in vitro study, 100 mg/day equivalent (0.01 ug/ml) thiamine was used. Based on recent publications, we compared the results of the IL-17 response from our clinical and in vitro study to those found in other proinflammatory disease conditions (metabolic conditions, septic shock, viral infections and COVID-19), including symptoms, and dose ranges of effective and safe administration of thiamine. We developed a dose range and pharmacokinetic profile for thiamine as a novel intervention strategy in COVID-19 to alleviate the effects of the cytokine storm and neurological symptoms. Results The DC group showed significantly elevated proinflammatory cytokines compared to HV. Three-week of 200 mg daily thiamine treatment significantly lowered the baseline IL-17 levels while increased IL-22 levels (anti-inflammatory response). This was validated by an in vitro macrophage response using a lower thiamine dose equivalent (100 mg), which resulted in attenuation of IL-17 and elevation of IL-22 at the mRNA level compared to the ethanol-only treated group. In humans, a range of 79-474 mg daily of thiamine was estimated to be effective and safe as an intervention for the COVID-19 cytokine storm. A literature review showed that several neurological symptoms of COVID-19 (which exist in 45.5% of the severe cases) occur in other viral infections and neuroinflammatory states that may also respond to thiamine treatment. Discussion The Th17 mediated IL-17 proinflammatory response can potentially be attenuated by thiamine. Thiamine, a very safe drug even at very high doses, could be repurposed for treating the cytokine/immune storm of COVID-19 and the subsequent neurological symptoms observed in COVID-19 patients. Further studies using thiamine as an interventional/prevention strategy in severe COVID-19 patients could identify its precise anti-inflammatory role. worldwide. Emerging infectious diseases (EID) include viral pathogens that have shown higher 131 incidence of human infection in the past several decades and raise concerns regarding 132 increased ongoing/future prevalence 1 . Coronavirus is recognized as an EID that has become a 133 challenging and aggressive infection with high morbidity and mortality in humans 2 . SARS-CoV-2 134 (severe acute respiratory syndrome coronavirus 2; causes coronavirus disease ) was 135 identified in 2019, has become a pandemic, and is a priority healthcare concern in the year 136 2020 3 . 137 In viral infections, tissue inflammation is driven by multiple proinflammatory and 138 immunoregulatory signals 4,5 . The pathological progression of COVID-19 has multiple clinical 139 stages and may present with the cytokine storm syndrome 6 and immunosuppression 7 . 140 Interleukin-17 (IL-17) is a cytokine 8 that is often involved in a proinflammatory response in the 141 cytokine storm of viral infections 9-11 . It can also promote respiratory viral infections 12 , tissue 142 pathology 13-15 , and neurological manifestations 16 . Th17 cells also produce Interleukin-22 (IL-143 22), which plays a protective/anti-inflammatory role, and it is dysregulated in several 144 proinflammatory conditions 17 . Thus, a therapy that could alleviate the Th17 mediated pro-145 inflammatory response 18 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20177501 doi: medRxiv preprint part of a larger addiction intervention investigation. All of these patients also received thiamine 173 as part of the medical management, which is the primary aim of this study. Sixteen age-and 174 sex-matched male and female alcohol use disorder (AUD) patients (Termed as disease controls 175 [DC] in this investigation) between 21-65 yrs. of age with both present and past heavy drinking 176 profile participated as the DC, who were diagnosed with AUD based on DSM-IV TR criteria. 177 They received daily doses of open label thiamine (100 mg twice daily = 200 mg per day) 27 for 3-178 weeks after completion of the consenting process. DC patients also received standard of care 179 inpatient medical management, including counseling. Detailed information on subject 180 recruitment and management can be obtained from several of our previous publications 28-31 . 181 We also included eight healthy controls in this study for comparison with DC. Demographic data 182 were collected from all the participants. Baseline (HV and DC) and post-treatment (DC only) 183 blood samples (after the completion of 3-weeks of thiamine dosing) were collected, processed 184 (for plasma extraction) and frozen at -80°C. They were subsequently thawed and assayed. Total RNA was extracted from the cells using Trizol reagent (500 µl/well) according to 215 manufacturer's instruction (Life Technologies, Carlsbad, CA) and reverse-transcribed using 216 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. and Leigh's disease 40 (Medline Plus: Thiamine). We also included the recorded thiamine dose 232 levels from the DC group (AUD with Wernicke Korsakoff Syndrome, WKS 41 ; from our clinical 233 study) as one of the pro-inflammatory conditions. 234 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 25, 2020. (low end), the slopes used to identify AUC in blood were 2.14, and 1.76 in plasma . For the 474 250 mg thiamine dosing (upper end), the slope used to derive AUC in blood was 1.02, while in 251 plasma it was 1.09. Similarly, for the 79 mg thiamine dosing, the slope used to derive Cmax in 252 blood was 0.40, and in plasma it was 0.39. For the 474 mg thiamine dose, the slope used to 253 derive AUC in blood was 0.14, and in plasma it was 0.18. 254 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 25, 2020. . Table 1 as well as in Figures 256 1 and 2. Two-sided Student's t-test was used to examine the difference between disease 257 controls and healthy volunteers at baseline (see Suppl. Table 1 and Fig. 1) , and two-sided 258 Student's paired t-test was used to examine the changes at baseline versus 3 weeks for disease 259 controls (Figure 1) . between-group ANOVA was used to evaluate demographic and cytokine profiles (Table 1) We conducted a review on the neurological presentation in COVID-19 and other 271 relevant viral occurrences of encephalitis (Table 1) . We identified and tabulated the 272 neurological symptoms of COVID-19 and viral encephalitis from the recently published findings. 273 We also described the neurological symptoms, that are generally treated effectively with 274 thiamine (Table 1) . We used PubMed and Medline Plus for disease references (searched until 275 August 5, 2020). 276 277 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20177501 doi: medRxiv preprint Demographics and Candidate Proinflammatory Cytokine Profile 279 DC group individuals in this study had significantly higher age than the healthy controls 280 (HV) (Suppl Table 1 ). However, there was no significant difference in the mean BMIs between 281 the two groups, and the sex-distribution was also similar between the two groups. Both IL-6 (~6 282 fold) and IL-1β (~3 fold) cytokines were significantly higher in the DC group (AUD patients) 283 compared to the healthy controls/volunteers (HV) group. IL-10 was also numerically higher in 284 the DC group. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 25, 2020. Figures 3A and 3B) , since the IL-17 levels are much higher in COVID-19 than in 317 the reports from many other proinflammatory disease conditions. Using regression analysis, a 318 range of 79 mg/day (lower end of dose range) -474 mg/day (higher end of dose range) for 319 thiamine administration was found to correspond to a range of 15-40 ng/mL level of IL-17 used 320 in vitro. 321 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20177501 doi: medRxiv preprint The pharmacokinetic parameters were: Area Under the Curve (AUC), and Maximum (or 322 peak) Concentration of a drug (Cmax). These gave a very close estimation of the specific oral 323 thiamine dose (Figure 4) . As expected, plasma values were higher for both AUC and Cmax at 324 higher doses and were lower at lower doses (Suppl Table 2 ). 325 326 We tabulated the neurological symptoms from the recently published findings on 329 COVID-19 (Table 1) . Severely ill COVID-19 patients presented with various neurologic symptoms 330 that could be grouped together as: acute cerebrovascular disease; altered mental status; and 331 musculoskeletal symptoms 51 . We also included the neurological presentation commonly 332 observed in viral encephalitis of non-COVID-19 origin, grouped corresponding to the 333 presentation of the symptoms of COVID-19. 334 Lastly, we also tabulated the neurological symptoms that are commonly treated with 335 thiamine. Several neurological symptoms of COVID-19 and viral encephalitis corresponded well 336 with the neurological spectrum that is known to be managed effectively with thiamine. 337 338 We evaluated individuals with significantly altered IL-17 and IL-22 responses associated 340 with Th17 cells and found a significant role for a 3-week 200 mg/daily thiamine treatment 341 regimen in improving the Th17 response in the AUD disease control patient cohort whose 342 members exhibited a high pro-inflammatory status at baseline. SARS CoV-2 viral challenge 343 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 25, 2020. suggesting IL-17 as a potential therapeutic target. Proinflammatory IL-17 production could also 364 initiate pulmonary eosinophilic response, by promoting proliferation of eosinophils in the bone 365 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 25, 2020. showed Wernicke's encephalopathy in 10% of the cases) 65 , and these conditions are associated 385 with thiamine deficiency. It is possible that patients with viral infection could have an increased 386 risk of thiamine deficiency, but this information has remained largely unexplained in viral 387 diseases 66 , including COVID-19. A potential reason could be that a deficiency in thiamine could 388 be related to the thiamine transport protein, which can have a general preference for multiple 389 membrane transport molecules which can function as receptors for candidate viruses 67 . The 390 Th17 proinflammatory response has also been reported in the experimental encephalomyelitis 391 Our study has several limitations. This is a small study. However, both clinical and in 402 vitro evidence collectively support the potential of thiamine as a therapeutic agent in 403 attenuating the Th17 proinflammatory response. We did not test the in vitro/in vivo efficacy of 404 thiamine in the treatment of COVID-19 or its derivative stimulated Th17 proinflammatory 405 response directly. We anticipate conducting such in vitro experiments for COVID-19 as a 406 continuation of this project. Moreover, plasma thiamine levels have not been assessed in 407 COVID-19. Our study did not have sufficiently large numbers of males and females; thus, 408 identifying sex-differences was not within the scope of this study. 409 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20177501 doi: medRxiv preprint In summary, Thiamine has been approved by the Food and Drug Administration (FDA) of 410 the USA as a prescription product and is considered very safe even at higher doses since it is 411 water soluble and can be excreted via urine, if in excess 68 . Given its robust safety record, we 412 suggest that thiamine should be considered for COVID-19 treatment studies. 413 Tables 415 Table 1 Hemorrhages 71 Cerebrovascular All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 25, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20177501 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 25, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20177501 doi: medRxiv preprint Urbanization and disease emergence: 464 dynamics at the wildlife-livestock-human interface. Trends in ecology & evolution Emergence of a novel human coronavirus threatening human health. 467 Nature medicine The continuing 2019-nCoV 469 epidemicthreatof novel coronaviruses to global health: the latest 2019 novel 470 coronavirus outbreak in Wuhan, China The trinity of COVID-19: immunity, 475 inflammation and intervention CoV-2: a storm is raging COVID-19: 479 consider cytokine storm syndromes and immunosuppression. The Lancet IL-17: prototype member of an emerging cytokine family. 482 Journal of leukocyte biology Deficiency of autophagy protein Map1-484 LC3b mediates IL-17-dependent lung pathology during respiratory viral infection via ER 485 stress-associated IL-1 IL-17 level in patients with Dengue virus infection & 487 its association with severity of illness Neutralization of IL-17 inhibits the production of anti-ANT 490 autoantibodies in CVB3-induced acute viral myocarditis. International 491 immunopharmacology IL-17-induced pulmonary pathogenesis during 493 respiratory viral infection and exacerbation of allergic disease. The American journal of 494 pathology Expression of interleukin-17 associated with disease 496 progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. 497 Diagnostic pathology IL-17 response mediates acute lung injury induced by the 2009 499 pandemic influenza A (H1N1) virus Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ 501 lymphocytes is associated with mucosal damage in SIV infection Encephalitis as a clinical manifestation of COVID-19. Brain, behavior, 504 and immunity. 2020. 505 17. Eyerich K, Dimartino V, Cavani A. IL-17 and IL-22 in immunity: Driving protection and 506 pathology COVID-19: a case for inhibiting IL-17? The role of thiamine in nervous tissue Immunohistochemical expression of 514 proinflammatory cytokines IL-1β, IL-6, TNF-α and involvement of COX-2, quantitatively 515 confirmed by Western blot analysis, in Wernicke's encephalopathy. Pathology-Research 516 and Practice Outcome of thiamine treatment in 567 a child with Leigh disease due to thiamine-responsive pyruvate dehydrogenase 568 deficiency Thiamine for prevention and 570 treatment of Wernicke-Korsakoff Syndrome in people who abuse alcohol. Cochrane 571 Database of Systematic Reviews Clinical features of patients infected with 2019 novel 573 coronavirus in Wuhan, China. The lancet TH17 responses in cytokine storm of COVID-19: An emerging target of 575 JAK2 inhibitor Fedratinib Elevated plasma level of selective cytokines in COVID-19 577 patients reflect viral load and lung injury Wojas-Pelc A. 579 The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis 580 factor α in patients with metabolic syndrome accompanying severe psoriasis and 581 psoriatic arthritis IL-17 in synovial fluids from patients with 584 rheumatoid arthritis is a potent stimulator of osteoclastogenesis. The Journal of clinical 585 investigation Increased 587 percentages of T helper cells producing IL-17 and monocytes expressing markers of 588 alternative activation in patients with sepsis Alterations of T helper lymphocyte subpopulations in sepsis, severe 590 sepsis, and septic shock: a prospective observational study Critical role of IL-17RA in immunopathology of 593 influenza infection Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, 595 and IL-23, in inflammatory diseases Neurological manifestations of hospitalized patients with 598 COVID-19 in Wuhan, China: a retrospective case series study Interleukin 17 is a chief orchestrator of immunity Role of IL-1 Beta in the Development of Human TH 607 17 Cells: Lesson from NLPR3 Mutated Patients Interleukin 10 suppresses Th17 cytokines secreted by 609 macrophages and T cells Thiamine deficiency promotes T cell infiltration in experimental 611 autoimmune encephalomyelitis: the involvement of CCL2 IL-17 Plays a Role in Respiratory Syncytial Virus-induced Lung 614 Inflammation and Emphysema in Elastase and LPS-injured Mice Interleukin-17 drives pulmonary 617 eosinophilia following repeated exposure to Aspergillus fumigatus conidia. Infection and 618 immunity Thiamine disulfide as a 620 potent inhibitor of human immunodeficiency virus (type-1) production. Biochemical and 621 biophysical research communications Thiamine deficiency and Wernicke's encephalopathy in AIDS Thiamine treatment of chronic hepatitis B infection. The 626 American journal of gastroenterology Combined vitamin C, hydrocortisone, and thiamine 628 therapy for patients with severe pneumonia who were admitted to the intensive care 629 unit: Propensity score-based analysis of a before-after cohort study Wernicke's encephalopathy: an unusual consequence 638 of the acquired immune deficiency syndrome-case report and literature review. Case 639 reports in medicine A putative thiamine transport protein is a 641 receptor for feline leukemia virus subgroup A Water-soluble vitamins, part II (folic acid, riboflavin, thiamine, vitamin B12) Chaudhuri A, Kennedy P. Diagnosis and treatment of viral encephalitis. Postgraduate 649 medical journal Wernicke's encephalopathy: new clinical settings and recent advances 651 in diagnosis and management. The Lancet Neurology Characteristics of ocular findings of patients with coronavirus 655 disease 2019 (COVID-19 COVID-19-Associated Miller Fisher Syndrome: MRI Findings Bilateral ocular paralysis: analysis of 31 inpatients. Archives of neurology Hedges III TR. Ophthalmoplegia associated with AIDS. Survey of ophthalmology Detection of coronavirus in the 669 central nervous system of a child with acute disseminated encephalomyelitis Viral encephalitis: familiar infections and emerging pathogens Acute hemorrhagic 674 leukoencephalitis manifesting as intracerebral hemorrhage associated with herpes 675 simplex virus type I Severe psychological distress among patients with epilepsy 679 during the COVID-19 outbreak in southwest China Viral encephalitis and epilepsy Phenobarbital and symptom-triggered lorazepam versus 684 lorazepam alone for severe alcohol withdrawal in the intensive care unit 690 Neuropathology of COVID-19: a spectrum of vascular and acute disseminated 691 encephalomyelitis (ADEM)-like pathology Rao R, Topiwala A. Alcohol use disorders and the brain A New Symptom of COVID-19: Loss of Taste and Smell Olfactory and gustatory dysfunctions 699 as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-700 19): a multicenter European study Hypogeusia, dysgeusia, hyposmia, and dysosmia following 705 influenza-like infection Utility of hyposmia and hypogeusia for the 708 diagnosis of COVID-19. The Lancet Infectious Diseases. 2020. 709 97. Azhideh A. COVID-19 Neurological Manifestations Rose AS, Jacobson BM. Treatment of trigeminal neuralgia with vitamin B1 (thiamine 718 hydrochloride) Therapy of neuropathies with a vitamin B combination Symptomatic treatment of painful diseases of the peripheral nervous system with a 721 combination preparation of thiamine, pyridoxine and cyanocobalamin Characteristic ECG manifestations in patients with COVID-19 Cardiac and arrhythmic 726 complications in patients with COVID-19 Fatal encephalitis due to Nipah virus among pig-729 farmers in Malaysia. The Lancet Di Napoli R. Features, evaluation and 731 treatment coronavirus (COVID-19) StatPearls Publishing; 2020. 732 106. Ripamonti E, Gaffuri M, Molteni F. Cognitive, neuropsychiatric, and motor profile in post 733 tick-borne flaviviral encephalomyelitis. Neurological Sciences Signs of preclinical Wernicke's encephalopathy and 735 thiamine levels as predictors of neuropsychological deficits in alcoholism without 736 Korsakoff's syndrome Altered motor cortex excitability to 738 magnetic stimulation in alcohol withdrawal syndrome. Alcoholism: clinical and 739 experimental research Abnormality of a thiamine-requiring enzyme in patients with 741 Wernicke-Korsakoff syndrome Miller Fisher syndrome No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity